Navigation Links
Halozyme to Host Second Quarter 2013 Financial Results Conference Call
Date:7/31/2013

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2013 on Wednesday, August 7, 2013 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 418819.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
2. Halozyme Reports First Quarter 2012 Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozyme Reports Second Quarter 2012 Financial Results
7. Halozyme to Host Third Quarter Financial Results Conference Call
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... , ... August 19, 2017 , ... ... that it is the first organization with pending recognition status from the Centers ... Program (“DPP”) via group telehealth classes and live video conferencing. , The ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... joined its Orlando location as an interventional pain management physician. He brings a ... the treatment of migraine headaches, and significant experience in spinal cord stimulation for ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport ... a definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner ...
Breaking Medicine News(10 mins):